Nov. 17, 2010 (Chicago) -- Doubling the dose of the anticlotting drug Plavix does not reduce heart attacks or deaths in certain high-risk people, a study shows.
The study participants were determined to be at high risk of cardiovascular complications after undergoing a test showing that their blood was still prone to clotting despite taking the anticlotting medication. Clots can lodge in an artery, causing a heart attack or stroke.
Whether the test, called platelet reactivity testing, should be given to people taking Plavix has been the subject of much debate.
"We're not set up to recommend it at this time," says Mariell Jessup, MD, medical director of the Penn Heart and Vascular Center at the University of Pennsylvania.
Some people are genetically predisposed to be poor metabolizers of Plavix, and they have higher rates of heart attacks, strokes, and death.
To compensate for this poor response, doctors often increase the dose of Plavix in these patients. But the strategy of using the platelet reactivity test to guide treatment with Plavix had not been evaluated in a large clinical trial until now.
Matthew Price, MD, of the Scripps Clinic in La Jolla, Calif., presented the findings at the American Heart Association annual meeting.
Using the platelet reactivity test, Price and colleagues identified more than 2,200 patients who were poor metabolizers of Plavix after taking the standard Plavix dose 12 to 24 hours after angioplasty and stenting, procedures that open blocked heart arteries.
The patients were then given either a high or a standard dose of Plavix for six months.